We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The new Bimzelx administration and dosage is available ...

The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active nonradiographic axial ...

Bimzelx is a brand-name biologic medication used to treat plaque psoriasis and other conditions by blocking specific immune system proteins that cause inflammation. More common side effects of Bimzelx ...

Bimzelx is prescribed for moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in ...

Mild side effects of Bimzelx include headache and injection site reaction. Serious side effects of Bimzelx include increased liver enzymes and inflammatory bowel disease. Some people taking Bimzelx ...

Bimzelx is a type of medicine called a monoclonal antibody. Monoclonal antibodies are human-made antibodies created in the lab to mimic antibodies in the body. Bimzelx works by blocking two naturally ...

(RTTNews) - UCB announced that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX is now available. These are in addition to the 1 mL device administration ...

OAKVILLE, ON, June 9, 2026 /CNW/ - UCB Canada Inc. today announced that Canada's Drug Agency (CDA-AMC) has issued a positive recommendation to reimburse BIMZELX® (bimekizumab injection) with ...

Following an examination of clinical evidence and stakeholder input, Canada's Drug Agency (CDA-AMC) has recommended BIMZELX® (bimekizumab injection) for reimbursement with conditions for patients with ...